The impact of GLP-1s on food and grocery
17 July 2025With the increasing adoption of weight loss medication, we explore the implications of GLP-1s on food and grocery.
Approaches to weight loss have evolved in recent years. Our latest report explores how the evolving landscape of weight loss is impacting shopping behaviour, and the implications for the food and grocery industry.
Our survey of 2000+ nationally representative British adults found that 3% have personally tried weight loss injections, with a further 26% knowing someone who has tried this medication. The halo effect for those taking GLP-1s could start to strongly influence the makeup and size of the household basket, and shift social occasions.
There is significant cross over between people who are using weight loss injections and the number of people who have tried more traditional dieting methods. With 11% of adults willing to try weight loss injections in the future, there is certainly appetite for the medication. Based on the current population, this could translate to approximately 6 million adults.
For adults who have personally tried the medication, or who know someone in their household that has, we asked them which dietary and lifestyle changes they had made or witnessed since starting. This included which food and grocery categories could be most impacted.
We also used social listening to observe what people were talking about online, in association with their GLP-1 journey. Areas covered in the report include:
Which food and grocery categories are subject to the most online discussion in association with weight loss journeys
The different types of protein-rich products featuring in these online conversations
How GLP-1 users are complementing their diet with supplements
The claimed side effects from GLP-1 medication
How people are holding themselves accountable
To find out more about the anticipated shopper shifts, varying perspectives towards GLP-1s, and opportunities for retailers, operators, and suppliers, you can read the report on ShopperVista now.
Our second report, available to Retail Analysis subscribers: Weight loss drugs: can GLP-1s solve the obesity crisis?
More on GLP-1
GLP-1 insights and solutions
Stay up to date with our latest research, impartial analysis, business intelligence, and guidance on this evolving trend.